Encephalocraniocutaneous lipomatosis

Encephalocraniocutaneous lipomatosis (ECCL) is a rare condition that primarily affects the brain, eyes, and skin of the head and face. Most of this condition's signs and symptoms are present from birth, and they vary widely among affected individuals.

A hallmark feature of ECCL is a noncancerous tumor under the scalp covered by a smooth, hairless patch of skin. This type of tumor, called a nevus psiloliparus, is made up of fatty tissue. Some people with ECCL also have noncancerous tumors under the skin elsewhere on the head or face. Many have small flaps of skin called skin tags on the eyelids and around the eyes. Hair loss (alopecia), thin or missing patches of skin on the scalp (dermal hypoplasia or aplasia), and changes in skin coloring (pigmentation) are also possible.

The most common eye abnormality in ECCL is a noncancerous growth called a choristoma. These growths can be present in one or both eyes and may affect vision.

About two-thirds of people with ECCL have noncancerous fatty tumors inside the brain or around the spinal cord. These tumors are called intracranial lipomas and intraspinal lipomas, respectively. Affected individuals also have an increased risk of developing a type of brain cancer called a glioma. The brain and spinal cord abnormalities associated with ECCL can cause seizures, abnormal tensing of the muscles, and intellectual disability ranging from mild to profound. However, about one-third of affected individuals have normal intelligence.

Other kinds of growths may also occur in people with ECCL, including noncancerous jaw tumors.

Frequency

ECCL is a rare disorder. Fewer than 60 cases have been reported in the medical literature.

Causes

ECCL can result from mutations in the FGFR1 gene, which provides instructions for making a protein called fibroblast growth factor receptor 1 (FGFR1). This receptor interacts with proteins called fibroblast growth factors (FGFs) to trigger signaling within cells. Signaling via the FGFR1 protein is involved in many critical processes, such as cell division and the regulation of cell growth and maturation. This signaling is important for the normal development and growth of several parts of the body, including the brain.

The FGFR1 gene mutations that cause ECCL arise randomly in one cell during the early stages of development before birth. As cells continue to grow and divide, some cells will have the mutation and others will not. This mixture of cells with and without
a genetic mutation is known as mosaicism. In cells with an altered \textit{FGFR1} gene, the resulting \textit{FGFR1} protein is overactive, triggering abnormal signaling that affects cell growth and division. Researchers are studying how these changes in signaling lead to the growth of noncancerous tumors and the other features of ECCL.

In some people with ECCL, no \textit{FGFR1} gene mutation has been identified, and the cause of the disease is unknown. Other genetic changes are under study as possible causes of this condition.

\textbf{Inheritance Pattern}

This condition is described as sporadic because it occurs in people without a history of the disorder in their family. Because ECCL results from mosaic gene mutations, which occur after conception, individuals do not inherit the condition from their parents.

\textbf{Other Names for This Condition}

- ECCL
- Fishman syndrome (formerly)
- Haberland syndrome (formerly)

\textbf{Diagnosis & Management}

\textbf{Genetic Testing Information}

- What is genetic testing? \\
  /primer/testing/genetictesting

- Genetic Testing Registry: Encephalocraniocutaneous lipomatosis \\

\textbf{Other Diagnosis and Management Resources}

- American Brain Tumor Association: Brain Tumor Diagnosis \\
  https://www.abta.org/about-brain-tumors/brain-tumor-diagnosis/

- American Brain Tumor Association: Brain Tumor Treatment & Care \\
  https://www.abta.org/about-brain-tumors/brain-tumor-treatments-care/

\textbf{Additional Information & Resources}

\textbf{Health Information from MedlinePlus}

- Encyclopedia: Cutaneous Skin Tag \\
  https://medlineplus.gov/ency/article/000848.htm

- Encyclopedia: Seizures \\
  https://medlineplus.gov/ency/article/003200.htm

- Health Topic: Benign Tumors \\
  https://medlineplus.gov/benigntumors.html
• Health Topic: Brain Tumors
  https://medlineplus.gov/braintumors.html

• Health Topic: Eye Diseases
  https://medlineplus.gov/eyediseases.html

**Genetic and Rare Diseases Information Center**

• Encephalocraniocutaneous lipomatosis
  https://rarediseases.info.nih.gov/diseases/2108/encephalocraniocutaneous-lipomatosis

**Educational Resources**

• KidsHealth from Nemours: Neurocutaneous Syndromes

• MalaCards: encephalocraniocutaneous lipomatosis
  https://www.malacards.org/card/encephalocraniocutaneous_lipomatosis

• Merck Manual Consumer Version: Lipomas
  https://www.merckmanuals.com/home/skin-disorders/noncancerous-skin-growths/lipomas

• Orphanet: Encephalocraniocutaneous lipomatosis
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=2396

**Patient Support and Advocacy Resources**

• American Brain Tumor Association: Glioma
  https://www.abta.org/tumor_types/glioma/

• American Brain Tumor Association: Lipoma
  https://www.abta.org/tumor_types/lipoma/

• American Epilepsy Society
  https://www.aesnet.org/

• The Arc: For People with Intellectual and Developmental Disabilities
  https://www.thearc.org/

**Scientific Articles on PubMed**

• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28encephalocraniocutaneous+lipomatosis%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22+AND+human%5Bdp%5D

**Catalog of Genes and Diseases from OMIM**

• ENCEPHALOCRANIOCUTANEOUS LIPOMATOSIS
  http://omim.org/entry/613001
Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26942290
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800051/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16523517


  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19574261

Reprinted from Genetics Home Reference:

Reviewed: November 2016
Published: January 8, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services